Scope and Claims Dissection for US Patent 11,103,490 (Clevidipine Chelating-Agent + Oleic Acid Negative-Zeta/Controlled-Microbial-Growth Emulsion Formulations)
US 11,103,490 claims a clevidipine injectable emulsion formulation defined by (i) a clevidipine concentration range (0.005 to 1% w/v), (ii) an EDTA (or salt) chelating antimicrobial in a defined wt/v range, (iii) a lipid phase (2 to 30% w/v), (iv) specific emulsifier/lecithin-type surfactant options, (v) tonicity modifier (2 to 3% w/v), (vi) oleic acid as a required co-emulsifier, and (vii) controlled physical chemistry and/or microbiological performance features including negative zeta potential and pH 6.0 to 8.0 (and in dependent claims, an asserted zeta value and specific micro-growth limits). The estate’s effective scope is narrow-to-medium: it does not cover all clevidipine emulsions, only those meeting the full combination of ingredient-recitation limits plus the zeta potential and/or microbial-growth performance constraints.
What exactly do the claims of US 11,103,490 cover?
Independent claim 1: what must a product contain to infringe?
Claim 1 is a multi-element formulation claim. Infringement requires meeting every limitation below, not just clevidipine + an antimicrobial.
Core composition limitations
- Active: clevidipine (or pharmaceutically acceptable salt/ester) at 0.005 to 1% w/v.
- Antimicrobial: EDTA or an EDTA salt at 0.001 to 1.5% w/v.
- Lipid: at 2 to 30% w/v.
- Emulsifier: at 0.2 to 2.0% w/v.
- Tonicity modifier: at 2 to 3% w/v.
- Co-emulsifier: oleic acid at 0.01 to 2% w/v.
- Water: included.
- Antioxidant: one of a closed list (including sodium ascorbate; sodium citrate; cysteine HCl; sodium bisulfate; sodium metabisulfite; sodium sulfite ascorbyl palmitate; BHA; BHT; propyl gallate; tocopherol; or salt thereof).
Physical-chemical constraints
9. pH: 6.0 to 8.0.
10. Zeta potential: “negative zeta potential.”
Functional language that still constrains structure
- The antimicrobial agent is explicitly “a chelating agent,” and then narrowed to EDTA/salt.
- “Negative zeta potential” is a measurable physical-chemistry limitation.
Practical infringement implication
- A competitor can avoid claim 1 by changing any one required pillar: e.g., use a different chelator than EDTA, omit oleic acid (or replace with another co-emulsifier), eliminate the antioxidant from the enumerated list, shift pH outside 6.0–8.0, or produce an emulsion whose zeta potential is not negative under the patent’s assay conditions.
Dependent claim 2: tightens the EDTA range
Claim 2 narrows claim 1’s EDTA content to:
- Chelating agent (EDTA/salt): about 0.001 to 0.5% w/v.
Scope effect
- If a product uses EDTA within 0.5–1.5% w/v, it may still hit claim 1 but not claim 2.
Dependent claim 3: narrows lipid choices
Claim 3 limits lipid selection to a specified group:
- soybean oil, safflower seed oil, olive oil, cottonseed oil, sunflower oil, sesame oil, peanut oil, corn oil
- medium chain triglycerides, triacetin, propylene glycol diesters, monoglycerides
- mixtures of two or more.
Scope effect
- If a competitor uses an unlisted lipid, they avoid claim 3 but may remain within claim 1 if claim 1’s “lipid” limitation was intended to be broad. The excerpt you provided does not state claim 1’s lipid list; claim 3 explicitly supplies the list for that dependent claim.
Dependent claim 4: narrows emulsifier choices (lecithin/synthetic PC)
Claim 4 restricts the emulsifier selection to:
- egg yolk phospholipids, soybean phospholipids
- synthetic phosphatidyl cholines
- purified phosphatidyl cholines and hydrogenated phosphatidyl choline
- and mixtures.
Scope effect
- Similar: unlisted emulsifiers avoid claim 4 but do not necessarily avoid claim 1 depending on how broad claim 1’s emulsifier limitation is (your excerpt states only a concentration range in claim 1, not a list).
Dependent claim 5: narrower pH
- pH: about 7.0 to about 8.0.
Scope effect
- A formulation with pH 6.0–7.0 could avoid claim 5 while still falling into claim 1.
What do independent claims 6 and 7 add beyond claim 1?
Independent claim 6: adds a microbial-growth numeric performance limit
Claim 6 includes the same composition skeleton as claim 1:
- clevidipine 0.005–1% w/v
- EDTA (chelator) 0.001–1.5% w/v
- lipid 2–30% w/v
- emulsifier 0.2–2.0% w/v
- tonicity modifier 2–3% w/v
- co-emulsifier oleic acid 0.01–2% w/v
- water
- no antioxidant list recited in claim 6 per your excerpt (but claim 1 includes antioxidants).
Added performance limit
- “microbial growth is delayed or retarded such that there is less than 10-fold (1 log) increase in viable microbial colonies over a 24-hour period.”
Scope effect
- Claim 6 can catch formulations that meet the EDTA/oleic acid composition limits but may not match the zeta potential “negative” requirement of claim 1, depending on whether claim 6 omits zeta potential constraints in your excerpt (it does omit zeta potential in the text you provided).
Independent claim 7: fixes zeta potential to a specific value
Claim 7 similarly recites the full composition set, and adds:
- “pharmaceutical formulation has a zeta potential of 36.1.”
Conflict/interpretation with claim 1
- Claim 1 requires negative zeta potential.
- Claim 7 requires a positive zeta potential value (36.1).
This means the patent is internally supporting multiple formulation “states” that still meet some claimed objectives (composition and ingredient constraints are consistent; the physical-chemistry constraint differs). From a clearance perspective, this increases coverage because an infringer could plausibly be pushed into one theory or another depending on how their formulation measures.
Dependent claim 8: pins EDTA at 0.005% w/v and oleic acid at 0.03% w/v
Claim 8 adds exact-ish points:
- EDTA present at about 0.005% w/v
- oleic acid present at about 0.03% w/v
- pH: about 6.0 to about 8.0 (consistent with claim 1).
Scope effect
- A product matching claim 1 but with higher or lower EDTA/oleic acid could avoid claim 8 while still potentially infringing claim 1 or claim 2.
How narrow is the formulation coverage in practice? (Element-by-element “escape points”)
Below are the high-leverage design-outs from claim 1’s full set of limitations:
-
EDTA substitution
- Use a non-EDTA chelating antimicrobial (even if it is chelating).
- Or use EDTA at a concentration outside 0.001–1.5% w/v (or outside 0.001–0.5% w/v for claim 2).
-
Co-emulsifier substitution
- Replace oleic acid with a different co-emulsifier (or use oleic acid outside 0.01–2% w/v).
-
pH shift
- Move pH outside 6.0–8.0 (or outside 7.0–8.0 to evade claim 5).
-
Zeta potential steering
- Claim 1: “negative zeta potential.”
- Claim 7: zeta potential 36.1.
- A formulation that avoids both the negative condition and the specific 36.1 condition is a route to non-infringement, assuming the patent’s measurement method matches the competitor’s measurement.
-
Antioxidant list omission or substitution
- Claim 1 requires an antioxidant from a closed group. Using a different antioxidant system could evade claim 1 even if everything else matches.
-
Emulsifier/lipid selection
- Dependent claims 3 and 4 constrain the lipid and emulsifier choices. A product outside those lists can avoid dependent coverage.
-
Microbial performance target
- For claim 6, avoid by designing a microbial-growth profile that exceeds the “less than 1 log increase over 24 hours” threshold (again assuming the patent’s test method).
How strong is the patent estate likely to be from a claims-scope standpoint?
Based only on the claim language you provided, the strength profile is:
- High “specificity strength”: the claims are not general to “clevidipine emulsions”; they require a multi-variable recipe and physical performance properties.
- Moderate “design-around risk”: the multi-element structure gives competitors many potential escape points (switch chelator, switch co-emulsifier, adjust pH, adjust zeta potential, change antioxidant).
- High coverage breadth across variants within the recipe: the independent claims cover at least two different zeta-potential regimes (negative zeta in claim 1 versus fixed 36.1 in claim 7) while keeping the same core composition skeleton.
If there are additional claims in the full patent file wrapper (not provided in your excerpt) that include alternative salts, other antioxidants, other lipid classes, different zeta ranges, or other microbial endpoints, those would widen the estate. With only claims 1–8 in view, the coverage still appears focused on a particular clevidipine emulsion platform using EDTA as chelator, oleic acid as co-emulsifier, and tight pH/zeta or microbiological efficacy specifications.
What is the likely IP-landscape positioning for US 11,103,490 in clevidipine?
Category placement
US 11,103,490 sits in the “injectable emulsion formulation” bucket:
- active ingredient: clevidipine
- formulation differentiators: EDTA (chelator antimicrobial), oleic acid (co-emulsifier), antioxidant system, and emulsion charge characteristics (zeta potential), plus microbial control performance.
Competitive relevance
It is most relevant to:
- generics or authorized copies seeking FDA approval for a clevidipine injection that matches the EDTA/oleic acid emulsion characteristics, including zeta potential behavior and pH.
- formulation developers improving antimicrobial control in lipid emulsions (where EDTA and fatty-acid co-emulsifiers are common levers).
How many distinct formulation “sub-claims” does the excerpt imply?
From claims 1–8, you effectively have three overlapping claim theories:
- Claim 1 theory: EDTA + oleic acid + defined antioxidant + pH 6–8 + negative zeta.
- Claim 6 theory: EDTA + oleic acid + defined ranges + microbial-growth performance limit (less than 1 log over 24 hours).
- Claim 7 theory: EDTA + oleic acid + defined ranges + zeta potential fixed at 36.1.
The dependent claims 2, 3, 4, 5, and 8 tighten particular axes:
- EDTA concentration (claim 2, claim 8)
- lipid class (claim 3)
- emulsifier class (claim 4)
- pH subrange (claim 5)
- exact EDTA and oleic acid and pH (claim 8)
Key Takeaways
- US 11,103,490 claims clevidipine emulsion formulations defined by a strict recipe: clevidipine 0.005–1% w/v, EDTA antimicrobial 0.001–1.5% w/v, lipid 2–30% w/v, emulsifier 0.2–2.0% w/v, tonicity modifier 2–3% w/v, and oleic acid co-emulsifier 0.01–2% w/v, plus pH 6–8 (claim 1) and zeta potential conditions.
- Claim 1 requires negative zeta potential and a specific antioxidant from a closed list.
- Claim 6 swaps the zeta constraint for a microbial-growth performance metric: <1 log growth over 24 hours.
- Claim 7 fixes zeta potential to 36.1, creating coverage across different charge states while keeping the same recipe skeleton.
- Dependent claims narrow EDTA content, lipid options, emulsifier options, and pH subranges; claim 8 locks specific EDTA and oleic acid levels.
FAQs
-
Can a clevidipine emulsion avoid infringement by using a different chelator than EDTA?
Claim coverage in the excerpt is explicitly tied to EDTA (or EDTA salt) as the chelating antimicrobial.
-
Does the patent require oleic acid as the co-emulsifier in all independent claims shown?
Yes. Claim 6 and claim 7 also recite oleic acid as the co-emulsifier.
-
What is the practical difference between claim 1 and claim 6?
Claim 1 uses pH and zeta potential (negative) plus antioxidant selection; claim 6 uses a microbial-growth inhibition/performance threshold.
-
How do claims 1 and 7 handle zeta potential differently?
Claim 1 requires negative zeta potential; claim 7 requires a specific zeta potential value of 36.1.
-
What parameters are most likely to be targeted in a generic formulation to reduce patent risk?
EDTA identity and concentration, oleic acid identity and concentration, pH range, zeta potential profile, and antioxidant selection.
References
- US Patent 11,103,490 (claims 1-8 as provided).
